Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biovanta is a multi-ingredient therapeutic regimen developed by Applied Biological Laboratories Inc for the treatment of common cold symptoms and pharyngitis. It consists of a throat spray containing a Mucosal Immune Complex (MIC)—comprising lysozyme, lactoferrin, and aloe—combined with wintergreen oil (methyl salicylate) and menthol, used in conjunction with an oral aspirin tablet. The MIC components are natural proteins and compounds designed to protect respiratory epithelia and reduce inflammation, while aspirin and methyl salicylate act as cyclooxygenase (COX) inhibitors to reduce prostaglandin synthesis, thereby alleviating pain and systemic cold symptoms. Clinical data from Phase 1 trials indicate significant reductions in sore throat pain and improvements in cough, congestion, and headache within 36-48 hours.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biovanta Wintergreen Throat Spray + aspirin.